By Adrian Galbreth
A new study has suggested that the drug ranibizumab could play a role in helping to reduce the number of people suffering from age-related macular degeneration (AMD), it has been claimed.
According to a computer modeling study carried out at the Wilmer Eye Institute at Johns Hopkins University, Baltimore, the drug reduces the prevalence and severity of legal blindness and visual impairment caused by AMD in caucasians.
The report, published in the June issue of Archives of Ophthalmology, one of the JAMA/Archives journals, estimates that monthly ranibizumab usage among AMD sufferers would reduce the incidence of legal blindness over two years by 72 per cent.
"Based on results of the model designed for this study, the authors conclude that ranibizumab would have an effect on reducing the occurrence of visual blindness in individuals with AMD," the report stated.
According to a recent study at the University of Texas UT Southwestern Medical Center, blocking two tiny molecules of RNA, which is similar to DNA, appears to suppress the abnormal growth of blood vessels that occurs in degenerative eye disorders, including AMD.
by Martin Burns